About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Molecular Medical Imaging research group focuses its activity on deepening the molecular bases and developing new areas of research in molecular signaling pathways and the identification of new theranostic targets.
We promote the confluence of basic and clinical researchers, experts in imaging and molecular biology to provide:
In this context, the creation of a translational imaging unit constitutes a basic objective for the development of research aimed at the personalized treatment of patients.
The group is made up of medical specialists in molecular imaging, chemists and pharmacists specializing in tracer synthesis, and biomedical engineers and physicists specializing in image processing and tomography equipment. These are affiliated with different institutions, such as the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron University Hospital (HUVH) and the Institute of Diagnostic Imaging (IDI).
PMID: 33246573 Journal: MEDICINA CLINICA Year: 2021 Reference: Med Clin (Barc). 2021 Jan 22;156(2):102. doi: 10.1016/j.medcli.2020.10.011. Epub 2020 Nov 6. Impact factor: 1.725 Publication type: Letter or abstract Authors: Varona Porres, Diego, Simo, Marc, Sanchez, Ana Lucia, Cabanzo, Laura, Andreu, Jordi et al. DOI: 10.1016/j.medcli.2020.10.011
PMID: 33184988 Journal: Journal of Digestive Diseases Year: 2021 Reference: J Dig Dis. 2021 Jan;22(1):41-48. doi: 10.1111/1751-2980.12961. Epub 2020 Dec 22. Impact factor: 2.325 Publication type: Paper in international publication Authors: Vidal, Laura, Roson, Nuria, Mast, Richard, Armario, David, Merino, Xavier, Dopazo, Cristina, Blanco, Laia, Caralt, Mireia, Gomez, Concepcion, Balsells, Joaquim et al. DOI: 10.1111/1751-2980.12961
PMID: 33002230 Journal: JOURNAL OF SURGICAL ONCOLOGY Year: 2021 Reference: J Surg Oncol. 2021 Jan;123(1):71-79. doi: 10.1002/jso.26236. Epub 2020 Oct 1. Impact factor: 3.454 Publication type: Paper in international publication Authors: Esgueva, Antonio, Siso, Christian, Espinosa-Bravo, Martin, Sobrido, Carolina, Miranda, Ignacio, Salazar, Juan P, Rubio, Isabel T et al. DOI: 10.1002/jso.26236
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.
YSOTOPE, a DeepTech start-up with the mission to improve the use of immunotherapies through medical imaging, became part of the spin-off network of VHIR and successfully closed its first investment round of €150,000 with Biozell Ventures.
